Mizuho set a $63.00 price target on Aerie Pharmaceuticals (NASDAQ:AERI) in a research note issued to investors on Friday morning, TipRanks reports. The firm currently has a buy rating on the stock.
Several other analysts have also recently commented on the stock. Piper Jaffray Companies reduced their price objective on shares of Aerie Pharmaceuticals from $76.00 to $53.00 and set an overweight rating for the company in a research note on Thursday, August 8th. Cantor Fitzgerald reiterated an overweight rating and issued a $62.00 price objective (down previously from $85.00) on shares of Aerie Pharmaceuticals in a research note on Thursday, August 8th. JMP Securities reduced their price objective on shares of Aerie Pharmaceuticals from $58.00 to $52.00 and set a market outperform rating for the company in a research note on Thursday, August 8th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a sell rating to a hold rating and set a $31.00 price objective for the company in a research note on Friday, June 28th. Finally, HC Wainwright reiterated a buy rating and issued a $57.00 price objective on shares of Aerie Pharmaceuticals in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $58.83.
Shares of AERI stock traded down $0.45 during mid-day trading on Friday, hitting $19.71. The stock had a trading volume of 1,913,361 shares, compared to its average volume of 839,642. Aerie Pharmaceuticals has a fifty-two week low of $17.51 and a fifty-two week high of $60.81. The firm has a market cap of $814.04 million, a PE ratio of -4.24 and a beta of 0.53. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.52 and a quick ratio of 2.35. The company’s 50-day simple moving average is $20.93 and its 200-day simple moving average is $30.25.
In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Management Ii bought 189,555 shares of the company’s stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $24.43 per share, for a total transaction of $4,630,828.65. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Vicente Anido, Jr. bought 26,250 shares of the company’s stock in a transaction on Monday, September 9th. The shares were acquired at an average price of $19.01 per share, with a total value of $499,012.50. Following the completion of the acquisition, the chief executive officer now directly owns 195,631 shares in the company, valued at approximately $3,718,945.31. The disclosure for this purchase can be found here. Insiders have acquired a total of 562,698 shares of company stock valued at $13,088,866 over the last 90 days. 8.71% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of AERI. Tower Research Capital LLC TRC grew its holdings in shares of Aerie Pharmaceuticals by 2,330.0% during the second quarter. Tower Research Capital LLC TRC now owns 1,458 shares of the company’s stock worth $43,000 after buying an additional 1,398 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of Aerie Pharmaceuticals during the second quarter worth about $115,000. Bank of Montreal Can grew its holdings in shares of Aerie Pharmaceuticals by 497.8% during the second quarter. Bank of Montreal Can now owns 4,023 shares of the company’s stock worth $119,000 after buying an additional 3,350 shares in the last quarter. First Mercantile Trust Co. purchased a new stake in shares of Aerie Pharmaceuticals during the second quarter worth about $134,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Aerie Pharmaceuticals during the second quarter worth about $276,000.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Featured Article: What moving averages are used to define a golden cross?
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.